Phase II study of neo-adjuvant gemcitabine plus epirubicin in primarily unresectable locally advanced breast cancer

Breast Journal

Volumn 14, Issue 4, 2008, Pages 397-398

  Silva, Juan Alejandro ^a   Pérez, Mario ^a   Rivera, Samuel ^a   Olivares, Guillermo ^a   Lira Puerto, Victor ^b   Castañeda, Noel ^c   Morales, Flavia ^c   Calderillo, Germáin ^c   Alcedo, Juan Carlos ^d   Onate Ocana F ^c   Gallardo, Dolores ^c   De La Garza, Jaime ^c  

^a HOSPITAL DE ONCOLOGÍA   (Mexico)

^b Centro Medico ABC   (Mexico)

^c INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^d Instituto Oncologico Nacional   (Panama)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE;

ADJUVANT THERAPY; ADVANCED CANCER; ALOPECIA; ANEMIA; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; FEBRILE NEUTROPENIA; HUMAN; INFECTION; LETTER; LEUKOPENIA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; STOMATITIS; TREATMENT RESPONSE; TUMOR VOLUME; VOMITING; ADULT; AGED; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DISEASE COURSE; FEMALE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; SEGMENTAL MASTECTOMY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; DISEASE PROGRESSION; EPIRUBICIN; FEMALE; HUMANS; LEUKOPENIA; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOADJUVANT THERAPY; TREATMENT OUTCOME;

EID: 54049124728     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/j.1524-4741.2008.00611.x     Document Type: Letter

References (8)

1. Heinemann V. Role of gemcitabine in the treatment of advanced and metastatic breast cancer. Oncology 2003;64:191-206 (Review).
2. Mross K, Bohn C, Edler L, et al. Randomized phase II study of single-agent epirubicin +/-verapamil in patients with advanced metastatic breast cancer. An AIO clinical trial. Ann Oncol 1993;4:45-50.
3. Heidemann E, Steinke B, Hartlapp J, et al. Randomized clinical trial comparing mitoxantrone with epirubicin and with doxorubicin, each combined with cyclophosphamide in the first-line treatment of patients with metastatic breast cancer. Onkologie 1990;13:24-7.
4. Gundersen S, Kvinnsland S, Klepp O, Lund E, Host H. Weekly Adriamycin vs. 4-epidoxorubicin every second week in advanced breast cancer. A randomized trial. The Norwegian Breast Cancer Group. Eur J Cancer 1990;26:45-8.
5. Silva A, Gonzalez H, Perez M, Rivera S, Lira-Puerto V, Castaneda N, et al. Neoadjuvant gemcitabine plus epirubicin in locally advanced breast cancer: evidence of activity in a phase II study. Proc Am Soc Clin Oncol 2002;21:51b (abstr #2015).
6. Schneeweiss A, Huober J, Sinn H-P, et al. Gemcitabine, epirubicin and docetaxel as primary systemic therapy in patients with early breast cancer: results of a multicentre phase I II study. Eur J Cancer 2004;40:2432-8.
7. Yardley DA, Whitworth PW, Greco FA, Burris HA, White M, Thomas M, et al. Preliminary results of a phase II trial of neoadjuvant gemcitabine, epirubicin, and docetaxel (GET) for inflammatory and locally advanced breast cancer (LABC). Proc Am Soc Clin Oncol 22: 2003 (abstr 287).
8. Sanchez-Rovira P, Duenas B, Cidraque M, et al. Dose-dense and sequential combination of epirubicin and cyclophosphamide followed by paclitaxel and gemcitabine 7plusmn; trastuzumab as neoadjuvant chemotherapy in stage II and III breast cancer. A phase II and pharmacogenomic study. Proc Am Soc Clin Oncol 2004; 23: 29c (abstr #608).